Janux Therapeutics, Inc. (JANX)
NASDAQ: JANX · Real-Time Price · USD
44.31
-0.48 (-1.07%)
Jan 31, 2025, 10:34 AM EST - Market open
Janux Therapeutics Revenue
Janux Therapeutics had revenue of $439.00K in the quarter ending September 30, 2024, a decrease of -82.56%. This brings the company's revenue in the last twelve months to $13.05M, up 54.12% year-over-year. In the year 2023, Janux Therapeutics had annual revenue of $8.08M, down -6.14%.
Revenue (ttm)
$13.05M
Revenue Growth
+54.12%
P/S Ratio
175.80
Revenue / Employee
$203,891
Employees
64
Market Cap
2.55B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 8.08M | -529.00K | -6.14% |
Dec 31, 2022 | 8.61M | 4.98M | 136.79% |
Dec 31, 2021 | 3.64M | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.95B |
JANX News
- 6 days ago - Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer - Business Wire
- 23 days ago - Janux Therapeutics: mCRPC TAM And Promising JANX007's Phase 1 Data - Seeking Alpha
- 4 weeks ago - Best-Performing Stocks Of 2024 - Seeking Alpha
- 7 weeks ago - Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million - Business Wire
- 2 months ago - Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants - Business Wire
- 2 months ago - Janux Therapeutics Announces Proposed Public Offering - Business Wire
- 2 months ago - Janux Therapeutics' Prostate Cancer Trial Data Exceeds Investor Expectations: Analyst - Benzinga
- 2 months ago - Janux Therapeutics Stock Soars 70% on Prostate Cancer Drug Trial Results - Barrons